Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review/meta-analysis. ^[1]
• Intravenous ferric carboxymaltose is probably superior to intravenous iron sucrose for increasing hemoglobin by 20 g/L or 10 g/L (relative risk (RR) 1.25, 95% confidence interval (CI) 1.06 to 1.46, Number Needed to Treat for Benefit (NNTB) = 9).
• Oral ferric maltol shows superiority over placebo for increasing hemoglobin levels (RR 73.00, 95% CI 4.58 to 1164.36).
• Intravenous iron preparations may lead to more responders compared to oral iron (RR 1.17, 95% CI 1.05 to 1.31, NNTB = 11), with fewer withdrawals due to adverse events (RR 0.39, 95% CI 0.20 to 0.74).
• No significant differences in serious adverse events or therapy withdrawals were found between the studied intervention agents; however, the certainty of these findings is very low due to risk of bias and imprecision.
• Withdrawals due to adverse events may be greater with oral iron preparations compared to intravenous iron (15/554 vs. 31/373, RR 0.39, 95% CI 0.20 to 0.74, low-certainty).
• There is no population types or subgroups information available in the reviewed studies.